#1 Clinical Trials Search in Europe

Urapidil

Clinical trials are investigating Urapidil in people with acute ischemic stroke. The main goal is to compare blood pressure management strategies after mechanical thrombectomy and measure recovery at 90 days. The study looks at whether a protocol using Urapidil can improve outcomes in this target group.

Table of Contents

Trial overview

The available trial data describe the HOPE study, which investigated Urapidil in people with acute ischemic stroke.[1] This was an interventional study, meaning the researchers assigned treatment strategies and then compared the results.[1] The study is listed as completed and included 814 participants.[1]

Study design and treatment groups

The trial compared standard blood pressure management after mechanical thrombectomy with a protocol aimed at hemodynamic optimization.[1] In simple terms, the study asked whether a more tailored blood pressure strategy could improve recovery after the clot-removal procedure.[1] The intervention list shows Urapidil as one of the study drugs used intravenously in the trial.[1]

Who participated

The target population was people with acute ischemic stroke who had undergone mechanical thrombectomy.[1] The source data do not provide more detailed entry rules, such as age limits or other selection criteria.[1]

Main outcome measured

The primary outcome was the modified Rankin Scale (mRS) score at 90 days after randomization.[1] This scale is used to measure disability and daily function after stroke, so it helps show how well participants recovered.[1] The analysis planned a direct comparison between the two groups using an intention-to-treat analysis and a shift analysis of mRS scores, with the main effect reported as an odds ratio and 95% confidence interval.[1]

What the study setup means for patients

This trial was designed to see whether blood pressure control after thrombectomy could be improved by matching targets to the level of vessel reopening, also called recanalization.[1] The focus was not on long-term drug use, but on treatment decisions made during the stroke care period.[1] For patients and families, the key point is that the study tested whether a more personalized blood pressure plan could lead to better recovery after stroke.[1]

Trial ID Phase Condition studied Status Enrollment
2024-516642-19-01 Phase 3 Acute Ischemic Stroke Completed 814

FAQ

  • What is being studied in Urapidil clinical trials? The trial is studying blood pressure management after mechanical thrombectomy in acute ischemic stroke. It compares a standard approach with a protocol that uses hemodynamic optimization, meaning blood pressure targets are adjusted based on the treatment result.
  • Who can take part in the study? The trial focuses on people with acute ischemic stroke who undergo mechanical thrombectomy. The source data does not give more detailed participation rules.
  • What phase is the Urapidil trial? The HOPE study is a Phase 3 trial. Phase 3 studies usually compare treatments in larger groups to see how well they work in real clinical care.
  • What outcome is the trial measuring? The main outcome is the modified Rankin Scale, or mRS, at 90 days after randomization. This scale measures how well a person recovers after stroke and how much help they need in daily life.
  • Is the Urapidil study completed? Yes. The HOPE study is listed as completed. It enrolled 814 participants.

Ongoing Clinical Trials on Urapidil

  • Study on Blood Pressure Management with Urapidil, Phenylephrine, and Labetalol for Patients with Acute Ischemic Stroke After Endovascular Therapy

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Acute ischemic stroke: A sudden stroke caused by a blocked blood vessel in the brain. It can reduce blood flow and damage brain tissue.
  • Mechanical thrombectomy: A procedure that removes a clot from a blood vessel in the brain. It is used to restore blood flow during some strokes.
  • Blood pressure management: Careful control of blood pressure during treatment. In this trial, different blood pressure strategies are being compared.
  • Hemodynamic optimization: A treatment plan that aims to improve blood flow and circulation. In the study, it means using blood pressure targets based on how much the vessel was reopened.
  • Recanalization: The reopening of a blocked blood vessel. The trial uses the degree of recanalization to guide blood pressure targets.
  • Randomization: A method that assigns participants to study groups by chance. This helps make the comparison fair.
  • Intention-to-treat analysis: A way of analyzing results that keeps participants in the group they were first assigned to, even if treatment changes later.
  • Modified Rankin Scale (mRS): A scale used to measure disability and recovery after stroke. Lower scores usually mean better recovery.
  • Shift analysis: A method that looks at the full range of mRS scores, not just one cutoff point, to see whether results shift toward better recovery.
  • Confidence interval: A range that shows where the true study result is likely to be. It helps show how precise the result is.

References

  1. https://clinicaltrials.gov/study/2024-516642-19-01